|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Roche
|
|
gptkbp:acquisition
|
gptkb:Genentech
gptkb:Tibotec_Pharmaceuticals
|
|
gptkbp:capital
|
approximately 200 billion CHF (2021)
|
|
gptkbp:ceo
|
gptkb:2008
gptkb:Severin_Schwan
|
|
gptkbp:clinical_trial
|
data-driven decision making
collaborative approach
over 1,000 ongoing (2021)
Phase I, II, III, and IV
patient-centric focus
|
|
gptkbp:collaborations
|
government agencies
academic institutions
biotech companies
|
|
gptkbp:employees
|
around 100,000 (2020)
|
|
gptkbp:founded
|
gptkb:1896
|
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:headquarters
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche Pharma
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
over 20,000 active patents
|
|
gptkbp:language_of_instruction
|
over 50 new molecular entities
|
|
gptkbp:marketed_as
|
gptkb:Avastin
gptkb:Tecentriq
gptkb:Cotellic
gptkb:Tamiflu
gptkb:Perjeta
gptkb:Herceptin
gptkb:Rituxan
gptkb:Xolair
gptkb:Ocrevus
gptkb:Actemra
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Sanofi
gptkb:Pfizer
gptkb:Novartis
|
|
gptkbp:philanthropy
|
gptkb:Roche_Foundation
|
|
gptkbp:products
|
biopharmaceuticals
diagnostics
|
|
gptkbp:regulatory_compliance
|
FDA, EMA, and others
|
|
gptkbp:research
|
gptkb:2019
gptkb:Levi_Garraway
|
|
gptkbp:research_and_development
|
approximately 12 billion CHF (2020)
|
|
gptkbp:research_areas
|
rare diseases
cardiovascular diseases
ophthalmology
metabolic diseases
|
|
gptkbp:research_focus
|
oncology
central nervous system disorders
infectious diseases
immunology
|
|
gptkbp:revenue
|
58.3 billion CHF (2020)
|
|
gptkbp:stock_exchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Roche_Pharma_AG
gptkb:Roche_Diagnostics
|
|
gptkbp:sustainability_initiatives
|
diversity and inclusion
access to healthcare
environmental responsibility
|